Alnylam Pharmaceuticals ALNY Zilebesrian — Effective interest rate (as percent)
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Alnylam Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DebtInstrumentInterestRateEffectivePercentage.
The source filing: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 8:11 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001178670-26-000062
The debt obligations to repay Blackstone Life Sciences for the vutrisiran and zilebesiran funding are accreted from the initial carrying amount to the total payment amount using the effective interest rate method over the life of the Development Funding Agreement. The effective interest rate is determined based on the proceeds received and projections of the amounts and timing of the future cash flows. The accretion is recorded as interest expense in the condensed consolidated statements of operations and comprehensive income (loss). We recognize the proceeds received and the principal portion of payments made to Blackstone Life Sciences as financing activities within the condensed consolidated statements of cash flows. As of June 30, 2026 and December 31, 2025, our estimates of total interest expense resulted in an effective annual interest rate of 51% and 46%, respectively, related to vutrisiran and 31% and 32%, respectively, related to zilebesiran.
Cover / Front Matter
FAQ
- What is Alnylam Pharmaceuticals's zilebesrian — effective interest rate (as percent)?
- Alnylam Pharmaceuticals (ALNY) reported zilebesrian — effective interest rate (as percent) of 31% in Q2 2026.
- What does zilebesrian — effective interest rate (as percent) mean?
- The effective interest rate represents the actual annual cost of borrowing associated with financing arrangements specific to the Zilebesrian program. It reflects the true yield or cost of capital after accounting for the amortization of any related discounts or premiums. This metric is critical for assessing the cost-efficiency of non-dilutive funding strategies used to advance clinical development.
Ask your AI about Alnylam Pharmaceuticals's zilebesrian — effective interest rate (as percent).
Connect your AI assistant and compare segments, right in your chat.
